KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Return on Equity (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Return on Equity for 10 consecutive years, with 0.2% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity rose 54.0% year-over-year to 0.2%, compared with a TTM value of 0.2% through Dec 2025, up 54.0%, and an annual FY2025 reading of 0.21%, up 50.0% over the prior year.
  • Return on Equity was 0.2% for Q4 2025 at Teva Pharmaceutical Industries, up from 0.11% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.2% in Q4 2025 and bottomed at 0.38% in Q1 2021.
  • Average Return on Equity over 5 years is 0.14%, with a median of 0.12% recorded in 2022.
  • The sharpest move saw Return on Equity crashed -35bps in 2021, then skyrocketed 54bps in 2025.
  • Year by year, Return on Equity stood at 0.04% in 2021, then tumbled by -805bps to 0.28% in 2022, then skyrocketed by 70bps to 0.08% in 2023, then tumbled by -300bps to 0.33% in 2024, then surged by 161bps to 0.2% in 2025.
  • Business Quant data shows Return on Equity for TEVA at 0.2% in Q4 2025, 0.11% in Q3 2025, and 0.04% in Q2 2025.